evaluation safety and efficacy of nerve allograft MegaNerve Prime® in breast reconstructio
- Conditions
- Neoplasms
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 40
1) Patients over 19 to under 80 years of age
2) Patients scheduled to undergo direct to implant (DTI) for breast cancer
3) Patients who agree to a clinical study and can follow up during the trial period
4) Patients with peripheral nerve damage or nerve defect due to disease and trauma
1) Patients undergoing chemotherapy for cancer other than breast cancer
2) Patients with confirmed local recurrence or systemic metastasis of breast cancer
3) Patients with a history of ipsilateral breast surgery
4) Patients with underlying diseases such as infectious diseases, autoimmune diseases (especially rheumatic diseases, etc.), and blood clotting disorders
5) Patients with systemic diseases other than breast cancer (especially uncontrolled diabetes, etc.)
6) Pregnant or lactating women
7) Other patients who are judged to be difficult to participate in the research by the principal investigator
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Semmes Weinstein Monofilaments(SWMF)
- Secondary Outcome Measures
Name Time Method Semmes Weinstein Monofilaments(SWMF);BREAST-Q Assessment;Sensory satisfaction assessment